No Data
No Data
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36
Express News | Cullinan Therapeutics Receives Approval to Initiate Its Global Phase 1 Clinical Trial of Cln-978
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
Express News | Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for Cln-978 to Treat Systemic Lupus Erythematosus